Patritumab (Anti-ERBB3 / HER3)

Patritumab (Anti-ERBB3 / HER3) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. MW: 145.5 KD.
Supplier Selleck Chemicals
Product # A2506
Sku # A2506-1mg*25
Pricing 1mg*25, $2970.00
Feedback